search
Back to results

Probiotic Supplementation in the Dysbiosis of Bowel Preparation

Primary Purpose

Microbial Colonization, Irritable Bowel Syndrome, Metabolic Syndrome

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Infloran probiotic
HAC probiotic
Infloran placebo
HAC placebo
Sponsored by
National Taiwan University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Microbial Colonization

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Adults age >20
  2. Undergoing colonofibroscopy (CFS) with PEG bowel preparation

Exclusion Criteria:

  1. Inadequate bowel preparation
  2. Subjects with active cancer or IBD (inflammatory bowel disease)
  3. Subjects with history of abdominal surgery (including stomach, gallbladder, pancreas, small bowel, large bowel)
  4. Subjects who take medication related to gastrointestinal motility within 1 months
  5. Subjects who take antibiotics or probiotics within 1 months
  6. Subjects under pregnancy
  7. Allergic or intolerance to the study medication
  8. Refused to randomization

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Placebo Comparator

    Experimental

    Experimental

    Arm Label

    Placebo

    HAC

    Infloran

    Arm Description

    Placebo HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks

    Probiotic HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks

    Placebo HAC two packs once daily; Probiotic Infloran one pill three times per day for 8 weeks

    Outcomes

    Primary Outcome Measures

    Alpha diversity
    Change in alpha diversity of bacterial species post-bowel preparation between probiotic group and placebo group.
    Beta diversity
    Change in beta diversity of bacterial species post-bowel preparation between probiotic group and placebo group.
    Bacterial species abundance
    Change in abundance of bacterial species post-bowel preparation between probiotic group and placebo group.

    Secondary Outcome Measures

    Incidence of functional bowel symptoms
    Incidence of GI associated symptoms in 8 weeks (abdominal discomfort, diarrhea, constipation, bloating) after bowel preparation between probiotic group (L) and placebo group (P).
    BMI
    Change in BMI pre- and post-bowel preparation after probiotic or placebo supplementation
    Insulin resistance
    Change in HOMA-IR pre- and post-bowel preparation after probiotic or placebo supplementation
    Dyslipidemia
    Change in lipid profiles (T-CHO, LDL, HDL, TG in mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
    Total cholesterol
    Change in Total cholesterol (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
    LDL
    Change in Low density lipoprotein, LDL (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
    HDL
    Change in high density lipoprotein, HDL (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
    TG
    Change in triglyceride, TG (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
    Weight
    Change in weight (Kg) pre- and post-bowel preparation after probiotic or placebo supplementation
    Waist
    Change in Waist (cm) pre- and post-bowel preparation after probiotic or placebo supplementation
    Fatty liver (grade)
    Change in fatty liver severity (grade) pre- and post-bowel preparation after probiotic or placebo supplementation
    Fatty liver (CAP)
    Change in fatty liver severity (CAP, dB/m) pre- and post-bowel preparation after probiotic or placebo supplementation

    Full Information

    First Posted
    February 19, 2021
    Last Updated
    February 25, 2021
    Sponsor
    National Taiwan University Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04774042
    Brief Title
    Probiotic Supplementation in the Dysbiosis of Bowel Preparation
    Official Title
    Probiotic Supplementation in the Dysbiosis of Bowel Preparation
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2021
    Overall Recruitment Status
    Unknown status
    Study Start Date
    March 2021 (Anticipated)
    Primary Completion Date
    January 2023 (Anticipated)
    Study Completion Date
    January 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    National Taiwan University Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Significant changes in gut microbiota was noted after the high-volume bowel preparation with PEG before colonoscopy. The dynamic changes were found to be short-term. However, the perturbation pattern of gut microbiota found after bowel preparation may link to metabolic syndrome and obesity. No study had investigated the supplementation of probiotic in this dynamic situation before. Here we proposed this study to fulfill the knowledge gap and also inquiry on the potential therapeutic strategy.1.To test the hypothesis of probiotic supplementation after bowel preparation alters the composition of gut microbiota in a short-term and long-term manner.2.To test the hypothesis of GI tract associated symptoms affected by probiotic supplementation after bowel preparation. 3. To test the hypothesis of clinical events, especially parameters of metabolic syndrome affected by probiotic supplementation after bowel preparation.
    Detailed Description
    Objectives: Colonoscopy is widely used for identification and treatment of colon polyps and intestinal symptoms. High-volume polyethylene glycol (PEG) bowel preparation prior to colonoscopy causes significant dysbiosis of gut microbiota. Currently dysbiosis of gut microbiota is associated with metabolic syndrome and obesity. However, inconclusive conclusions were drawn from clinical trials studying supplementary probiotics and beneficial clinical effects on metabolic parameters. However, no study has addressed the effects of probiotic supplementation on the labile and dynamic intestinal environment following bowel preparation. Aims: Our study aims at studying the short-term and long-term changes on gut microbiota following the probiotic supplementation after bowel preparation. We also aim at studying the changes in abdominal symptoms and parameters of metabolic syndrome. Methods: This study is a prospective, multicentered, randomized double blind three-armed placebo-controlled trial. Targeted population will be those undergoing PEG bowel preparation before colonoscopy. Each individual will be randomly assigned to one of the active probiotic or placebo supplementation. General health parameters and anthropometric measurements, stool, serum lab data, abdominal sonography, oral carnitine/choline challenge tests will be analyzed. The follow-up timepoints are pre- and post-bowel preparation, receiving probiotics/placebo for 8 weeks, 3 months and 6 months thereafter.Outcome measurement: Primary end point: Evaluate the chronological change of gut microbiota post-bowel preparation between probiotic group and placebo group. Secondary end points:To compare incidence of GI associated symptoms after taking probiotics between two groups. Also evaluate the effects of probiotic supplementation on parameters of metabolic syndrome, evaluate the effects on fatty liver and the interaction between SNP variation and the benefit of probiotic supplementation.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Microbial Colonization, Irritable Bowel Syndrome, Metabolic Syndrome

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    300 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Placebo HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
    Arm Title
    HAC
    Arm Type
    Experimental
    Arm Description
    Probiotic HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks
    Arm Title
    Infloran
    Arm Type
    Experimental
    Arm Description
    Placebo HAC two packs once daily; Probiotic Infloran one pill three times per day for 8 weeks
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Infloran probiotic
    Intervention Description
    Infloran
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    HAC probiotic
    Intervention Description
    HAc probiotic
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Infloran placebo
    Intervention Description
    Infloran placebo
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    HAC placebo
    Intervention Description
    HAC placebo
    Primary Outcome Measure Information:
    Title
    Alpha diversity
    Description
    Change in alpha diversity of bacterial species post-bowel preparation between probiotic group and placebo group.
    Time Frame
    32 weeks
    Title
    Beta diversity
    Description
    Change in beta diversity of bacterial species post-bowel preparation between probiotic group and placebo group.
    Time Frame
    32 weeks
    Title
    Bacterial species abundance
    Description
    Change in abundance of bacterial species post-bowel preparation between probiotic group and placebo group.
    Time Frame
    32 weeks
    Secondary Outcome Measure Information:
    Title
    Incidence of functional bowel symptoms
    Description
    Incidence of GI associated symptoms in 8 weeks (abdominal discomfort, diarrhea, constipation, bloating) after bowel preparation between probiotic group (L) and placebo group (P).
    Time Frame
    32 weeks
    Title
    BMI
    Description
    Change in BMI pre- and post-bowel preparation after probiotic or placebo supplementation
    Time Frame
    32 weeks
    Title
    Insulin resistance
    Description
    Change in HOMA-IR pre- and post-bowel preparation after probiotic or placebo supplementation
    Time Frame
    32 weeks
    Title
    Dyslipidemia
    Description
    Change in lipid profiles (T-CHO, LDL, HDL, TG in mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
    Time Frame
    32 weeks
    Title
    Total cholesterol
    Description
    Change in Total cholesterol (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
    Time Frame
    32 weeks
    Title
    LDL
    Description
    Change in Low density lipoprotein, LDL (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
    Time Frame
    32 weeks
    Title
    HDL
    Description
    Change in high density lipoprotein, HDL (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
    Time Frame
    32 weeks
    Title
    TG
    Description
    Change in triglyceride, TG (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation
    Time Frame
    32 weeks
    Title
    Weight
    Description
    Change in weight (Kg) pre- and post-bowel preparation after probiotic or placebo supplementation
    Time Frame
    32 weeks
    Title
    Waist
    Description
    Change in Waist (cm) pre- and post-bowel preparation after probiotic or placebo supplementation
    Time Frame
    32 weeks
    Title
    Fatty liver (grade)
    Description
    Change in fatty liver severity (grade) pre- and post-bowel preparation after probiotic or placebo supplementation
    Time Frame
    32 weeks
    Title
    Fatty liver (CAP)
    Description
    Change in fatty liver severity (CAP, dB/m) pre- and post-bowel preparation after probiotic or placebo supplementation
    Time Frame
    32 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Adults age >20 Undergoing colonofibroscopy (CFS) with PEG bowel preparation Exclusion Criteria: Inadequate bowel preparation Subjects with active cancer or IBD (inflammatory bowel disease) Subjects with history of abdominal surgery (including stomach, gallbladder, pancreas, small bowel, large bowel) Subjects who take medication related to gastrointestinal motility within 1 months Subjects who take antibiotics or probiotics within 1 months Subjects under pregnancy Allergic or intolerance to the study medication Refused to randomization
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Tzu-Chan Hong, M.D.
    Phone
    886-2-972653917
    Email
    edisonhong77@gmail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Li-Chun Chang, M.D. Ph.D.
    Organizational Affiliation
    National Taiwan University Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Probiotic Supplementation in the Dysbiosis of Bowel Preparation

    We'll reach out to this number within 24 hrs